
Kymera Therapeutics, Inc.: updates and filings
Price
$115.31
November 20, 2026Market cap $9.4B
What Ploutos Investor adds for Kymera Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 7 fiscal years, from 2019
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Oct 29, 2026next Feb 1, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
October 2026
August 2026
June 2026
April 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Oct 29, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 29, 2026Results of operationsForm8-K
- Oct 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Sep 8, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 5, 2026Results of operationsForm8-K
- Jul 27, 2026Officer or director change, Regulation FD disclosureForm8-K
- Jun 26, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Jun 25, 2026Regulation FD disclosure, other material eventsForm8-K
- Jun 24, 2026Shareholder voteForm8-K
- Jun 8, 2026Officer or director changeForm8-K
- May 15, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 6, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Apr 30, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 30, 2026Results of operationsForm8-K
- Apr 29, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 29, 2026Additional annual meeting materialFormDEFA14A
- Apr 29, 2026Annual meeting proxy statementFormDEF 14A
- Mar 27, 2026Amended articles or bylawsForm8-K
- Mar 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 26, 2026Material agreement entered, material agreement ended, other material eventsForm8-K
- Feb 26, 2026Shares registered for employeesFormS-8
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Oct 29, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 29, 2026 | 8-K | Results of operations | Document |
| Oct 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Sep 8, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 5, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 5, 2026 | 8-K | Results of operations | Document |
| Jul 27, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Jun 26, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Jun 25, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Jun 24, 2026 | 8-K | Shareholder vote | Document |
| Jun 8, 2026 | 8-K | Officer or director change | Document |
| May 15, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 6, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Apr 30, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 30, 2026 | 8-K | Results of operations | Document |
| Apr 29, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 29, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 29, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 27, 2026 | 8-K | Amended articles or bylaws | Document |
| Mar 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 26, 2026 | 8-K | Material agreement entered, material agreement ended, other material events | Document |
| Feb 26, 2026 | S-8 | Shares registered for employees | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jun 22, 2020.
The full analysis
What do Kymera Therapeutics's filings show?
The filings are where every one of Kymera Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.